Skip to main content
. Author manuscript; available in PMC: 2017 Oct 1.
Published in final edited form as: J Am Geriatr Soc. 2016 Sep 14;64(10):1988–1995. doi: 10.1111/jgs.14301

Figure 1.

Figure 1

Percentage of participants with acute myelogenous leukemia with impairment in geriatric assessment measures at baseline and after induction therapy (N = 49). Impairment is defined as scores on each measure as follows: Modified Mini-Mental State (3MS) examination <77; Eastern Cooperative Oncology Group (ECOG) >1; Center for Epidemiologic Studies Depression Scale (CES-D) >16; Distress >4; Short Physical Performance Battery (SPPB) <9; Pepper Assessment Tool for Disability (PAT-D) instrumental activity of daily living (IADL) subscale >1; PAT-D activity of daily living (ADL) subscale >1; PAT-D Mobility subscale >1.